A new combination drug for PTSD is poised to break a 20-year treatment drought, but bureaucratic delays and pharmaceutical price battles threaten to deny veterans and working families real relief.
At a Glance
- The FDA advisory committee will review brexpiprazole plus sertraline for PTSD on July 18, 2025.
- Only two FDA-approved PTSD drugs exist, both SSRIs from the 1990s.
- Phase 3 trials show significant symptom relief with the new drug combination.
- The new therapy costs $1,471.50 monthly before insurance coverage.
- Big pharma and insurers prepare for fierce battles over drug approval and access.
FDA Prepares to Decide: Will Veterans Finally Get Relief?
For over two decades, American veterans and PTSD sufferers have relied on outdated treatments, as the FDA approved only two selective serotonin reuptake inhibitors (SSRIs)—sertraline and paroxetine—in the 1990s. Millions have endured debilitating symptoms while pharmaceutical companies and regulators delayed progress. Now, Otsuka Pharmaceutical and Lundbeck offer new hope with brexpiprazole (Rexulti) combined with sertraline. The FDA’s Psychopharmacologic Drugs Advisory Committee will review this application on July 18, 2025, a decision that could end years of stagnation if the agency resists bureaucratic inertia and entrenched interests.
Watch a report: FDA Faces Pressure on New PTSD Drug Approval
Phase 3 clinical trials, as detailed in an Otsuka Pharmaceutical press release, show that brexpiprazole plus sertraline delivers a statistically significant reduction in PTSD symptoms compared to sertraline alone. This breakthrough signals a rare advance in treatment after decades of limited options. Experts emphasize the urgent need for effective therapies for veterans and first responders. However, the therapy’s high cost—$1,471.50 per month before insurance—raises concerns about accessibility. The FDA’s decision will test whether it can overcome financial and political pressures to deliver real relief.
Big Pharma, Big Prices, and the Battle for Access
Progress comes with a steep price. Brexpiprazole’s monthly cost is among the highest for psychiatric drugs, and while Otsuka offers a savings program, this barely scratches the surface of the broader affordability crisis in American healthcare. Insurers are preparing for difficult negotiations over coverage, which could delay or restrict patient access. Historically, insurance companies have delayed covering costly psychiatric medications, citing expenses over patient benefit.
Pharmaceutical lobbyists, insurers, and government regulators are positioned to clash as they defend financial interests. Meanwhile, PTSD patients and families are caught in the crossfire. The critical question is whether the FDA and healthcare system will prioritize patients over profits this time. An article in Managed Healthcare Executive highlights the looming battle over pricing and access. Approval would mark a major shift, but without affordable insurance coverage, access could remain limited.
Expert Opinions: Hope, Hype, and the Need for Real Change
Leading psychiatrists praise the new therapy’s trial results. Dr. Roger McIntyre called the findings “positive and compelling,” highlighting the “tremendous unmet need” in PTSD treatment. Dr. Elspeth Ritchie noted that while adjunctive antipsychotics like brexpiprazole have been used in depression, this is the first robust evidence supporting its use in PTSD, signaling a potential treatment breakthrough.
Still, skepticism remains. Some experts warn that long-term safety data are lacking and question whether brexpiprazole’s benefits depend solely on combination with sertraline or could extend to other antidepressants. In today’s regulatory environment, calls for “more research” often mean more delays. Americans weary of bureaucratic stalling demand swift action and real solutions instead of uncertainty.
If the FDA approves brexpiprazole plus sertraline, it would break a 20-year drought in PTSD drug development and provide millions a new lifeline. But if regulatory inertia or corporate politics prevail, it will reinforce a pattern of missed opportunities and deepen frustration with a healthcare system that often fails those it is meant to serve, as warned in a recent FDA public advisory notice.
